Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with HL who have received ASCT in the previous 30-45 days~* Patients at high risk of residual HL post ASCT~* Histologically-confirmed HL~* ECOG of 0 or 1~* Adequate organ function~Exclusion Criteria:~* Previous treatment with brentuximab vedotin~* Previously received an allogeneic transplant~* Patients who were determined to have a best clinical response of progressive disease with salvage treatment immediately prior to ASCT~* History of another primary malignancy that has not been in remission for at least 3 years~* Post ASCT or current therapy with other systemic anti-neoplastic or investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brentuximab vedotin (Type: EXPERIMENTAL): brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion
- Placebo (Type: PLACEBO_COMPARATOR): placebo every 3 weeks by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).